Cervical cancer
Conditions
Interventions
Case series:4-6 cycles of consolidation chemotherapy
Sponsors
Yantai Yuhuangding Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. voluntarily as the subject, sign the informed consent; 2. patients aged 18-65 years; 3. pathologic tissues were clearly diagnosed as cervical cancer,unoperated advanced cervical cancer with paraventral lymph node metastasis; 4. physical condition score is 0, 1 and 2; 5. invasive cervical squamous cell carcinoma, adenocarcinoma, or adenocarcinoma confirmed by biopsy; 6. FIGO stage IB-IIA stage; 7. detection of bone marrow, liver function and renal function: (1) bone marrow function WBC is greater than or equal to 3.5 x 10^9/L; Neutrophilic granulocytes are greater than or equal to 1.5 x 10^9/L; Platelets are greater than or equal to 100x 10^9/L. Hemoglobin greater than or equal to 100 g/L (acceptable with blood transfusion or other methods); (2) the liver function was in the normal range: alanine aminotransferase (ALT), aspartate aminotransferase (AST) 60ml /min; Calculation formula: CCr=(140-age) x weight (kg)/[72 x Scr(mg/dl)] or CCr=[(140-age) x weight (kg)]/[0.818 x Scr(umol/L)]; (4) the original international ratio of thrombin (INR) is less than or equal to 1.5.
Exclusion criteria
Exclusion criteria: (1) women during pregnancy and lactation; (2) patients who are allergic to platinum drugs; (3) a history of other malignant tumors; (4) abnormal blood routine: neutrophil < 1.5x10^9/L, HB <80g/L, PLT< 80x10^9/L; Abnormal liver function: transaminase was 2 times higher than normal; Renal function, urine routine and ecg abnormality; (5) participating in other clinical trials; (6) have had systemic chemotherapy in the last 3 years; (7) there has been a history of pelvic or abdominal radiotherapy before, which may cause the irradiation field overlapping; (8) there are distant metastatic lesions in other organs; (9) there are the following severe active concomitant diseases: edema has unstable angina or/and congestive heart failure requiring hospitalization in the past 6 months;Injection occurred in the last 6 months during a transmural myocardial infarction;Severe arteriosclerosis and hypertension;An acute bacterial or fungal infection at the time of registration requires intravenous antibiotic therapy;Chronic obstructive pulmonary disease or other respiratory diseases should be treated in the hospital or in the way of research.Liver dysfunction leads to jaundice or coagulation disorders and serious renal insufficiency;Patients with severe mental disorders;Severe haematopoietic system disease;Acquired immunodeficiency disease (HIV testing is denied to patients who have been diagnosed with or suspected to have HIV);Other immunocompromised (e.g., organ transplantation, long-term use of glucocorticoids); (10) other participants were deemed unsuitable by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free progression survival (PFS);Overall survival (OS);Recent adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor progression time (TTP);Long-term toxic and side effects; | — |
Countries
China
Contacts
Public ContactFang Zhou
Yantai Yuhuangding Hospital
Outcome results
None listed